8th April 2020
ExactCure to help reduce medication errors during the pandemic
The solution, named “Digital Twin”, simulates the efficacy and interactions of medicines in a patient’s body based on their personal characteristics (for example age, weight, renal failure, and genotype)
Using “Digital Twin”, ExactCure can help organisations in treating and monitoring the COVID-19 outbreak in the following ways:
- By providing personalised simulations of drugs being tested against COVID-19 throughout Europe (for example hydroxychloroquine, which has many known interactions and lopinavir/ritonavir) as well as supporting drugs (e.g. paracetamol as opposed to Nonsteroidal Anti-Inflammatory Drugs)
- By providing a tool for healthcare professionals to adapt their dosage according to patients’ characteristics, to avoid under-doses, overdoses and drug-drug interactions
- Monitoring remotely and in real-time actual drug intakes, patient-reported effects and correlating the effect with the plasmatic concentration of the drug – therefore generating population statistics.
ExactCure is already testing 15 different drugs but are happy to prioritise other drugs depending on the urgency and validity of the request.
The offer is valid until December 31st.
Click here to email ExactCure for more information about their offer
ASK: Research contributors needed for CON-VICE study
University of Luxembourg needs European researchers to get in touch
OFFER: Funding available for COVID-19 research
Fondation Air Liquide are looking to fund European projects
ASK: Supporting the immunocompromised
Partners sought to advance neutralising antibody